Jornal de Imunologia Clínica e Celular
Acesso livre
ISSN: 2155-9899
ISSN: 2155-9899
Shuzhen Qi, Shuchang Hu, Min Zhou, Yingxia Gao, Yeli Wu, Zufeng Sun and Qingjie Hu
Objective: This study investigated total glucosides of paeony (TGP)'s effect on serum IL-17 and IL-25 concentrations in patients with chronic autoimmune urticaria (CAU).
Methods: 71 autologous serum skin test (ASST)+CAU patients were randomized into two groups: 35 patients orally received 0.6g TGP t.i.d. plus 10 mg mizolastines once daily for 12 weeks (Treatment Group). The remaining 36 patients orally received 10 mg mizolastines once daily for 12 weeks (Control Group). Additionally, 60 ASSTchronic spontaneous urticaria patients were used for baseline comparison. Serum IL-17 and IL-25 concentrations were measured and compared between the Treatment Group, Control group and the ASST- patients at baseline; they were further measured and compared between the Treatment and Control groups at weeks 4 and 12.
Results: Baseline serum IL-17 and IL-25 concentrations in the ASST+ patients (173.40 ± 76.33 pg/ml, 22.07 ± 11.41 pg/ml, respectively) were significantly higher than those in the ASST- patients (76.15 ± 91.04 pg/ml, 8.69 ± 10.00 pg/ml, respectively). Significantly lower concentrations of IL-17 (102.60 ± 42.39 vs. 149.00 ± 76.61, P=0.003) and IL-25 (10.92 ± 5.45 vs. 16.74 ± 9.34, P=0.003) were associated with the Treatment Group vs. the Control Group at week 12, but not at baseline or week 4. Finally, the Treatment Group had significantly decreased IL-17 and IL-25 concentrations vs baseline at week 12 but not week 4, whereas the Control Group's IL-17 and IL-25 concentrations didn't change significantly over the 12 weeks.
Conclusion: TGP significantly decreased serum IL-17 and IL-25 concentrations in patient with CAU at week 12. This provided basis for exploring TGP as an alternative treatment for CAU.